GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alimera Sciences Inc (STU:ASZ1) » Definitions » Shiller PE Ratio

Alimera Sciences (STU:ASZ1) Shiller PE Ratio : (As of May. 21, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Alimera Sciences Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Alimera Sciences Shiller PE Ratio Historical Data

The historical data trend for Alimera Sciences's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alimera Sciences Shiller PE Ratio Chart

Alimera Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Alimera Sciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Alimera Sciences's Shiller PE Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Alimera Sciences's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alimera Sciences's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Alimera Sciences's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Alimera Sciences's Shiller PE Ratio falls into.



Alimera Sciences Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Alimera Sciences's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Alimera Sciences's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.11/131.7762*131.7762
=-0.110

Current CPI (Mar. 2024) = 131.7762.

Alimera Sciences Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -1.766 100.560 -2.314
201409 -1.979 100.428 -2.597
201412 -2.798 99.070 -3.722
201503 -3.049 99.621 -4.033
201506 -2.539 100.684 -3.323
201509 -0.401 100.392 -0.526
201512 -3.305 99.792 -4.364
201603 -3.367 100.470 -4.416
201606 -2.002 101.688 -2.594
201609 -2.138 101.861 -2.766
201612 -1.280 101.863 -1.656
201703 -1.402 102.862 -1.796
201706 -0.534 103.349 -0.681
201709 -1.007 104.136 -1.274
201712 -1.267 104.011 -1.605
201803 -1.338 105.290 -1.675
201806 -0.770 106.317 -0.954
201809 5.013 106.507 6.202
201812 -0.264 105.998 -0.328
201903 -0.522 107.251 -0.641
201906 -0.938 108.070 -1.144
201909 -0.599 108.329 -0.729
201912 0.072 108.420 0.088
202003 -0.217 108.902 -0.263
202006 -0.453 108.767 -0.549
202009 -0.102 109.815 -0.122
202012 -0.148 109.897 -0.177
202103 -0.529 111.754 -0.624
202106 0.855 114.631 0.983
202109 -0.510 115.734 -0.581
202112 -0.522 117.630 -0.585
202203 -0.772 121.301 -0.839
202206 -0.426 125.017 -0.449
202209 -0.758 125.227 -0.798
202212 -0.510 125.222 -0.537
202303 -0.663 127.348 -0.686
202306 -1.218 128.729 -1.247
202309 -0.056 129.860 -0.057
202312 -0.066 129.419 -0.067
202403 -0.110 131.776 -0.110

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Alimera Sciences  (STU:ASZ1) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Alimera Sciences Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Alimera Sciences's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Alimera Sciences (STU:ASZ1) Business Description

Traded in Other Exchanges
Address
6310 Town Square, Suite 400, Alpharetta, GA, USA, 30005
Alimera Sciences Inc is a commercial-stage pharmaceutical company developing and commercializing ILUVIEN for the treatment of diabetic macular edema (DME), a leading cause of blindness, and outside the U.S. for non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). ILUVIEN is a sustained-release intravitreal implant that enables patients to maintain vision longer, and importantly, with fewer injections. The company commercializes ILUVIEN in the U.S., Europe, China and the Middle East.

Alimera Sciences (STU:ASZ1) Headlines

No Headlines